VIDEO: Anti-TNF therapy viable for first-line treatment of IBD
Click Here to Manage Email Alerts
In this Healio Gastroenterology video exclusive, Miguel Regueiro, MD, FACG, discussed how anti-TNF therapy should be used as first-line therapy for treatment of inflammatory bowel disease.
During the Advances in Inflammatory Bowel Diseases Annual Meeting, Regueiro, department chair of gastroenterology, hepatology and nutrition and vice chair of the Digestive Disease and Surgery Institute at the Cleveland Clinic, took part in a debate with Corey A. Siegel, MD, MS, section chief of gastroenterology and hepatology at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, on which therapy should be used first in patients with IBD.
“We have to find the best medicine for the right patient and make sure they adhere to the medicine,” Regueiro said. “There are a variety of advanced therapies, biologics and small molecules that are available and we have to weigh the safety and efficacy of these medicines and prescribing them.”
As he was on the side for anti-TNF therapy, Regueiro said anti-TNF therapy has been around for a while and there is good understanding of its safety and efficacy. In addition, he said physicians now know how to optimize anti-TNF therapy. Anti-TNFs are readily available to patients and most insurers and payers approve them are first-line therapy for IBD, Regueiro added.
Collapse
Regueiro M. Debate: Hit me with your best shot: Which biologic first? Anti-TNF. Presented at: Advances in Inflammatory Bowel Diseases Annual Meeting; Dec. 9-11, 2021 (virtual meeting).
Click Here to Manage Email Alerts